Skip to main content
Equibles
ACRS $3.87 +2.11%
ACRS logo
ACRS · Aclaris Therapeutics, Inc.
Track ACRS — free

Use ACRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.87 +0.08 (+2.11%) Q1 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$557.88M
Shares
147.20M
Volume · Oct 28 1.87M Avg daily vol (3M) 2.85M
All webcasts

Earnings call · FY2026 Q3

Aclaris Therapeutics, Inc. (ACRS) Q3 2026 Earnings Call

Concluded Oct 27, 2026
Oct 27, 2026 0 turns
Period
FY2026 Q3
Runtime
—
Sources
1 artifact
Open full screen 8-K

Executive readout · one minute

What the filings say

8-K earnings release · filed Oct 27, 2026
Aclaris Therapeutics reported ATI-052 achieved 45% placebo-adjusted EASI improvement at day 57 in atopic dermatitis and 59% FeNO reduction at day 15 in asthma, and plans a Phase 2b eosinophilic esophagitis trial in early 2027.

The audio replay and transcript follow the call.

Research coverage

1 live source

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Oct 27, 2026 Company webcastOpen the original investor-relations page
Full-screen source Call document

ACRS alerts

Aclaris Therapeutics, Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →